dc.contributor.author | Sarkissian, Angela | eng |
dc.contributor.author | Neher, Jon O. | eng |
dc.contributor.author | Singh, Ravipal | eng |
dc.contributor.author | St. Anna, Leilani | eng |
dc.date.issued | 2012 | eng |
dc.description.abstract | Venlafaxine reduces hot flashes more than placebo in women with a history of breast cancer; adverse effects include dry mouth and constipation (strength of recommendation [SOR]: B, randomized clinical trials [RCTs] with heterogeneous outcomes). Gabapentin also reduces hot flashes more than placebo (SOR: B, a single RCT); adverse effects include dizziness and somnolence (SOR: C, standard reference). After having tried both medications, women tend to prefer venlafaxine (SOR: C, open-label crossover trial). Treating hot flashes is an off-label use for both drugs. | eng |
dc.identifier.uri | http://hdl.handle.net/10355/16181 | eng |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Clinical Inquiries, 2012 (MU) | eng |
dc.relation.ispartofcommunity | University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network. | eng |
dc.relation.ispartofseries | Journal of family practice, 61, no. 12 (December 2012): 759+. | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.subject | hot flashes | eng |
dc.subject | preventative treatment | eng |
dc.subject | breast cancer | eng |
dc.subject | Gabapentin -- Effectiveness | eng |
dc.subject.lcsh | Venlafaxine -- Effectiveness | eng |
dc.subject.lcsh | Menopause -- Alternative treatment | eng |
dc.subject.lcsh | Breast -- Cancer -- Patients | eng |
dc.title | Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? | eng |
dc.type | Article | eng |